IL-12 drives the expression of the inhibitory receptor NKG2A on human tumor-reactive CD8 T cells Nature Communications - Effective strategies to enhance T cell anti-tumor cytotoxicity are pivotal to improve treatment outcomes. By analyzing tumor samples from patients with head and neck or...

Underscoring the complexity of #anticancer immunity, Dr Fesneau in the Duhen lab @ #EACRI showed that #IL-12, while driving CD8 T cells to CTL, also drives up-regulation of #immunoregulatory #NKG2A on human #tumor-reactive #CD8.
rdcu.be/d0A7V. Very nice work by a great group #FinishCancer

1102 The HLA-E/NKG2A axis is a dominant immunomodulatory pathway associated with distinct tumor mi... Background HLA-E is a non-classical HLA molecule that can engage the heteromeric inhibitory receptor NKG2A/CD94 to suppress T-cell/NK-cells. Blockade of NKG2A in combination with other immunostimulato...

The HLA-E/NKG2A axis is a dominant immunomodulatory pathway associated with distinct tumor microenvironment features in a subset of NSCLC | Journal for ImmunoTherapy of Cancer

Authors form Yale & AstraZeneca
#NKG2A #NSCLC